Balchem Co. (NASDAQ:BCPC - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Balchem in a research note issued on Monday, May 6th. HC Wainwright analyst R. Selvaraju expects that the basic materials company will post earnings per share of $1.04 for the quarter. HC Wainwright currently has a "Buy" rating and a $170.00 price target on the stock. The consensus estimate for Balchem's current full-year earnings is $4.10 per share. HC Wainwright also issued estimates for Balchem's Q4 2025 earnings at $1.12 EPS.
Balchem (NASDAQ:BCPC - Get Free Report) last announced its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.02. Balchem had a return on equity of 11.03% and a net margin of 12.35%. The company had revenue of $228.70 million for the quarter, compared to analyst estimates of $234.66 million. During the same quarter last year, the firm earned $0.66 EPS. Balchem's revenue for the quarter was down 1.6% compared to the same quarter last year.
Separately, StockNews.com lowered Balchem from a "buy" rating to a "hold" rating in a report on Thursday, April 25th.
Read Our Latest Stock Report on BCPC
Balchem Stock Performance
Shares of NASDAQ:BCPC traded down $2.20 during trading on Wednesday, hitting $153.28. 81,624 shares of the stock were exchanged, compared to its average volume of 104,826. Balchem has a 1-year low of $110.74 and a 1-year high of $159.52. The company has a market capitalization of $4.97 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 3.33 and a beta of 0.72. The company's fifty day simple moving average is $151.00 and its 200-day simple moving average is $141.21. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.72 and a current ratio of 2.61.
Insider Transactions at Balchem
In other Balchem news, CAO William A. Backus sold 7,000 shares of Balchem stock in a transaction on Monday, February 26th. The stock was sold at an average price of $155.19, for a total value of $1,086,330.00. Following the completion of the transaction, the chief accounting officer now owns 5,914 shares in the company, valued at approximately $917,793.66. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO William A. Backus sold 9,180 shares of the business's stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $156.37, for a total transaction of $1,435,476.60. Following the completion of the sale, the chief accounting officer now owns 12,914 shares in the company, valued at $2,019,362.18. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO William A. Backus sold 7,000 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $155.19, for a total transaction of $1,086,330.00. Following the completion of the sale, the chief accounting officer now owns 5,914 shares in the company, valued at $917,793.66. The disclosure for this sale can be found here. In the last quarter, insiders have sold 76,630 shares of company stock valued at $11,843,249. 1.77% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Balchem
Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Balchem by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 3,791,512 shares of the basic materials company's stock valued at $563,987,000 after buying an additional 30,868 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in Balchem by 3.9% during the first quarter. Conestoga Capital Advisors LLC now owns 1,125,384 shares of the basic materials company's stock worth $174,378,000 after buying an additional 42,172 shares during the last quarter. Geneva Capital Management LLC raised its position in Balchem by 0.5% during the fourth quarter. Geneva Capital Management LLC now owns 767,211 shares of the basic materials company's stock worth $114,123,000 after acquiring an additional 3,885 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Balchem by 1.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 687,485 shares of the basic materials company's stock valued at $102,265,000 after acquiring an additional 11,629 shares during the last quarter. Finally, Clearbridge Investments LLC grew its position in shares of Balchem by 0.5% in the 4th quarter. Clearbridge Investments LLC now owns 521,590 shares of the basic materials company's stock valued at $77,587,000 after acquiring an additional 2,801 shares during the period. 87.91% of the stock is owned by institutional investors.
About Balchem
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Stories
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
